Heart failure & cardiomyopathiesGuideline or statement
European Journal of Heart Failure Consensus Statement. Heart Failure Pharmacotherapy for Patients with Heart Failure with Reduced Ejection Fraction and Concomitant Atrial Fibrillation: Review of Evidence and Call to Action
- Consensus statement (narrative review)
Recommendations
As issued by the authors
Efficacy of the four cornerstone HFrEF therapies in patients with concomitant atrial fibrillation (AF) requires further prospective investigation
AF-specific challenges (arrhythmia-induced remodelling and cardiomyopathy) necessitate more individually tailored treatment
Dedicated clinical trials needed assessing heart failure (HF) therapies in AF subgroups (paroxysmal, long-standing persistent, permanent AF) and the benefit of heart rate and rhythm control strategies
Original publication
European Journal of Heart Failure Consensus Statement. Heart Failure Pharmacotherapy for Patients with Heart Failure with Reduced Ejection Fraction and Concomitant Atrial Fibrillation: Review of Evidence and Call to Action. Eur J Heart Fail. Published 22 October 2025. doi:10.1002/ejhf.70069
Summarised from the published abstract; every number is checked against it